Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the BISHOP study
Rattachement africain : br. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Patients with severe COVID-19 seem to evolve with a compromised antiviral response and hyperinflammation. Neutrophils are critical players in COVID-19. IL-17A plays a major role in protection against extracellular pathogens and neutrophil attraction/activation. We hypothesized that secukinumab, an anti-IL17A monoclonal antibody, could prevent the deleterious hyperinflammation in COVID-19.Methods BISHOP was a randomized, open-label, single-centre, phase-II controlled trial. Fifty adult patients hospitalized with PCR-positive Covid-19, were randomized 1:1 to receive 300 mg of secukinumab subcutaneously at day-0 plus standard of care (group A) or standard of care alone (group B). A second dose of 300 mg of secukinumab could be administered on day-7, according to staff judgement. The primary endpoint was ventilator-free days at day-28 (VFD-28). Secondary efficacy and safety outcomes were also explored.Results An intention-to-treat analysis showed no difference in VFD-28: 23.7 (95%CI 19.6–27.8) in group A vs. 23.8 (19.9–27.6) in group B, p = .62; There was also no difference in hospitalization time, intensive care unit demand and the incidence of circulatory shock, acute kidney injury, fungal or bacterial co-infections. There was no difference in the incidence of severe adverse events. Pulmonary thromboembolism occurred only in males and was less frequent in secukinumab-treated patients (4.2% vs. 26.2% p = .04). There was one death in each group. Upper airway viral clearance was also similar in both groups.Conclusion The efficacy of secukinumab in the treatment of Covid19 was not demonstrated. Secukinumab decreased pulmonary embolism in male patients. There was no difference between groups in adverse events and no unexpected events were observed.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the BISHOP study
- Date Crossref
- 29/04/2022
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hospital das Clínicas da Universidade Federal de Minas Gerais pays non établi dans la noticeÉtablissement de santé
-
Hospital Risoleta Tolentino Neves pays non établi dans la noticeÉtablissement de santé
-
Universidade Federal de Minas Gerais Rheumatology Unit pays non établi dans la noticeUniversité ou école supérieure
-
Universidade Federal de Lavras Department of Statistics pays non établi dans la noticeUniversité ou école supérieure
-
Dept. of Genetics pays non établi dans la noticeInstitution
-
Novartis pays non établi dans la noticeInstitution
-
Department of Biochemistry and Immunology UFMG pays non établi dans la noticeInstitution
Hospital das Clínicas da Universidade Federal de Minas Gerais, Hospital Risoleta Tolentino Neves et Rheumatology Unit — Universidade Federal de Minas Gerais, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.